The resubmission of the Biological License Application for N-803, a treatment for a specific type of bladder cancer, is a significant event for ImmunityBio. If approved, it could lead to increased revenues for the company, which would likely have a positive impact on the stock price. However, the market's reaction will depend on various factors, including the perceived likelihood of approval and the potential market size for the treatment.